SCHEMBL6480214

SCHEMBL6480214

NN(c1ccccn1)c1ncncn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38
NOS3 P29474 1/20 0.35
NOS1 P29475 1/20 0.35
NOS2 P35228 1/20 0.35
PI4KA P42356 1/20 0.35
PI4K2B Q8TCG2 1/20 0.35
PI4K2A Q9BTU6 1/20 0.35
PI4KB Q9UBF8 1/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
KDM4E B2RXH2 4/20 0.33
LMNA P02545 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
CYP1A2 P05177 1/20 0.33
POLB P06746 1/20 0.33
CCR1 P32246 1/20 0.33
CCR5 P51681 1/20 0.33
CCR8 P51685 1/20 0.33
METAP1 P53582 1/20 0.33
BLM P54132 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3127282 0.81 CYP2D6 (0.47) CYP2D6CYP2C19NOS3NOS1NOS2
SCHEMBL22086465 0.81 HSP90AA1 (0.39) CYP2D6CYP2C19NOS3NOS1NOS2
SCHEMBL28442615 0.80 CYP2D6 (0.40) CYP2D6CYP2C19NOS3NOS1NOS2
Hydrochloric Acid SCHEMBL8742974 0.79 CYP2D6 (0.45) CYP2D6CYP2C19NOS3NOS1NOS2
SCHEMBL22086466 0.76 L3MBTL1 (0.37) CYP2D6CYP2C19NOS3NOS1NOS2
SCHEMBL3361750 0.74 ALDH1A1 (0.42) CYP2D6CYP2C19NOS3NOS1NOS2
SCHEMBL3394969 0.74 HSP90AA1 (0.33) CYP2D6CYP2C19L3MBTL1KDM4ETDP1
SCHEMBL13338823 0.73 TAAR1 (0.41) CYP2D6CYP2C19L3MBTL1KDM4ELMNA
SCHEMBL8202219 0.69 CYP2D6 (0.48) CYP2D6CYP2C19NOS3NOS1NOS2
SCHEMBL18880684 0.69 NOS3 (0.36) CYP2D6CYP2C19NOS3NOS1NOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6864255-B2 Substituted triazinyl amide derivatives and methods of use AMGEN INC. (US) 2005-03-08 US disclosed
US-20030087908-A1 Substituted triazinyl amide derivatives and methods of use AMGEN INC. 2003-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030087908-A1 Substituted triazinyl amide derivatives and methods of use FLT4, FLT1, VEGFA CYP2D6 257/4885CYP2C19 214/4885NOS3 115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.